Catalyst Pharmaceuticals, Inc. (CPRX) News

Catalyst Pharmaceuticals, Inc. (CPRX)

Today's Latest Price: $3.48 USD

0.04 (1.16%)

Updated Nov 24 4:00pm

Add CPRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter CPRX News Items

CPRX News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest CPRX News From Around the Web

Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.

Catalyst to appeal ruling in favor of FDA decision on Firdapse's competitor drug

Catalyst Pharmaceuticals slides ([[CPRX]] -7.8%) after a federal judge upheld a previous rule from a Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus and dismissed the company’s lawsuit against the FDA regarding the approval of a rival drug, Ruzurgi for the treatment of Lambert-Eaton Myasthenic Syndrome ((LEMS)) from Jacobus...

Seeking Alpha | September 30, 2020

ROCE Insights For Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 …

Benzinga | August 14, 2020

Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

- Firdapse® Second Quarter Net Revenues of $29.6 Million - Health Canada Approves Marketing Authorization for Firdapse® for Treating LEMS Patients -…

GlobeNewswire | August 10, 2020

Earnings Preview: Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters …

Benzinga | August 7, 2020

Here's How Much Investing $1,000 In Catalyst Pharmaceuticals In 2010 Would Be Worth Today

Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Catalyst’s Solid Decade: One stock that kept pace over the last decade was biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in the past decade came in 2018 when the company’s Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan … Full story available on Benzinga.com

Benzinga | August 4, 2020

Catalyst Pharma down 13% on adverse ruling in FDA lawsuit

Catalyst Pharmaceuticals ([[CPRX]] -12.7%) is under pressure on 77% higher volume in reaction to an adverse development in its lawsuit against the FDA related to Firdapse (amifampridine phosphate), approved in the U.S. in November 2018 for adults with an autoimmune disorder called Lambert-Eaton syndrome ((LEMS)), an Orphan Drug-tagged indication which is...

Seeking Alpha | July 31, 2020

Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA

CORAL GABLES, Fla., July 31, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit against the FDA has filed a Report and Recommendation in which she recommends to the District Judge handling the case that she grant the FDA's and Jacobus' motions for summary judgement and deny Catalyst's motion for summary judgement. Catalyst is currently reviewing the Magistrate Judge's decision, which it believes to be incorrect as a matter of law, and intends to pursue the case further with the District Judge. The decision on whether to grant or deny Catalyst's motion for summary judgement remains with the District Judge handling the case. Patrick J. McEnany, the Company's...

Yahoo | July 31, 2020

Catalyst Pharma files for $200M mixed shelf

Catalyst Pharmaceuticals (CPRX) has filed a preliminary prospectus for a $200M mixed shelf offering....

Seeking Alpha | July 24, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Catalyst Pharmaceuticals, Inc. - CPRX

New York, New York--(Newsfile Corp. - July 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/catalyst-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, ...

Yahoo | July 16, 2020

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Catalyst Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims

NEW YORK, NY / ACCESSWIRE / July 14, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Catalyst Pharmaceuticals, Inc. (NASDAQ: ...

Yahoo | July 14, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6124 seconds.